These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34065924)

  • 1. Combined Administration of Fibrinogen and Factor XIII Concentrate Does Not Improve Dilutional Coagulopathy Superiorly Than Sole Fibrinogen Therapy: Results of an In-Vitro Thrombelastographic Study.
    Schneck E; Muelich M; Markmann M; Edinger F; Cooper N; Moeller A; Bein G; Hecker A; Koch C; Sander M; Wolff M
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34065924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative effects of plasma, fibrinogen concentrate, and factor XIII on ROTEM coagulation profiles in an in vitro model of massive transfusion in trauma.
    Schmidt DE; Halmin M; Wikman A; Östlund A; Ågren A
    Scand J Clin Lab Invest; 2017 Oct; 77(6):397-405. PubMed ID: 28632435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
    Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
    Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of different sources of fibrinogen supplementation on clot initiation and stability in a model of dilutional coagulopathy.
    Schäfer N; Driessen A; Bauerfeind U; Fröhlich M; Ofir J; Stürmer EK; Maegele M
    Transfus Med; 2016 Oct; 26(5):373-380. PubMed ID: 27506588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen and FXIII dose response effects on albumin-induced coagulopathy.
    Hanna J; Winstedt D; Schött U
    Scand J Clin Lab Invest; 2013 Oct; 73(7):553-62. PubMed ID: 24004348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro.
    Haas T; Cushing MM; Asmis LM
    Scand J Clin Lab Invest; 2018 May; 78(3):230-235. PubMed ID: 29446989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is dilutional coagulopathy induced by different colloids reversible by replacement of fibrinogen and factor XIII concentrates?
    Kind SL; Spahn-Nett GH; Emmert MY; Eismon J; Seifert B; Spahn DR; Theusinger OM
    Anesth Analg; 2013 Nov; 117(5):1063-71. PubMed ID: 24029856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose Factor XIII administration induces effective hemostasis for trauma-associated coagulopathy (TAC) both in vitro and in rat hemorrhagic shock in vivo models.
    Nagashima F; Inoue S; Koami H; Miike T; Sakamoto Y; Kai K
    J Trauma Acute Care Surg; 2018 Sep; 85(3):588-597. PubMed ID: 29851904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%.
    De Lorenzo C; Calatzis A; Welsch U; Heindl B
    Anesth Analg; 2006 Apr; 102(4):1194-200. PubMed ID: 16551923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
    Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.
    Shenkman B; Einav Y; Livnat T; Budnik I; Martinowitz U
    Blood Transfus; 2014 Jan; 12(1):78-84. PubMed ID: 24333083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry.
    Koller T; Kinast N; Castellanos AG; Garcia SP; Iglesias PP; Vintro XL; Arranz JM; Seto NV; García MVM; Moreno-Castaño AB; Aznar-Salatti J; Albaladejo GE; Diaz-Ricart M
    Scand J Trauma Resusc Emerg Med; 2021 Apr; 29(1):57. PubMed ID: 33836790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
    Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
    Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of fibrinogen-, factor VIII- and XIII-mediated clot propagation in gelatin haemodilution.
    Schramko AA; Kuitunen AH; Suojaranta-Ylinen RT; Niemi TT
    Acta Anaesthesiol Scand; 2009 Jul; 53(6):731-5. PubMed ID: 19239406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose fibrinogen versus a clinically recommended dose of fresh frozen plasma for reversal of dilutional coagulopathy in an in vitro model of severe hemodilution.
    Rosenthal C; Rau J; Volk T; Sander M; Ziemer S; Von Heymann C
    Minerva Anestesiol; 2014 Aug; 80(8):894-903. PubMed ID: 24398441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy.
    Fenger-Eriksen C; Tønnesen E; Ingerslev J; Sørensen B
    J Thromb Haemost; 2009 Jul; 7(7):1099-105. PubMed ID: 19422451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor XIII levels, clot strength, and impact of fibrinogen concentrate in infants undergoing cardiopulmonary bypass: a mechanistic sub-study of the FIBCON trial.
    Siemens K; Hunt BJ; Parmar K; Taylor D; Salih C; Tibby SM
    Br J Anaesth; 2023 Feb; 130(2):175-182. PubMed ID: 36371257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Factor XIII Deficiency in Patients with Multiple Trauma.
    Hetz M; Juratli T; Tiebel O; Giesecke MT; Tsitsilonis S; Held HC; Beyer F; Kleber C
    Injury; 2023 May; 54(5):1257-1264. PubMed ID: 36577625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free oscillation rheometry monitoring of haemodilution and hypothermia and correction with fibrinogen and factor XIII concentrates.
    Winstedt D; Tynngård N; Olanders K; Schött U
    Scand J Trauma Resusc Emerg Med; 2013 Mar; 21():20. PubMed ID: 23517637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.